File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of famciclovir to prevent HPV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation

TitleUse of famciclovir to prevent HPV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation
Authors
KeywordsAllogeneic Bone Marrow Transplantation
Famciclovir
Hepatitis B
Issue Date1998
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
Journal Of Hepatology, 1998, v. 28 n. 3, p. 359-368 How to Cite?
AbstractBackground/Aims: Reactivation of chronic hepatitis B viral infection causes significant morbidity and mortality after bone marrow transplantation. Recently, nucleoside analogues, such as famciclovir, were found to have a direct suppressive effect on hepatitis B virus replication in both in vitro and in vivo studies. We have studied the effect of famciclovir on the incidence of hepatitis B virus reactivation and hepatitis after allogeneic bone marrow transplantation. Methods: Eight hepatitis B surface antigen (HBsAg)-positive patients who received allogeneic bone marrow transplantation were given oral famciclovir 250 mg three times daily, starting at least 1 week prior to bone marrow transplantation and continuing for 24 weeks after transplantation. Clinical and serological outcomes in these patients were compared with 24 HBsAg-positive recipients of allogeneic bone marrow transplantation who did not receive famciclovir (historical controls). Results: After bone marrow transplantation, there were five patients with hepatitis B virus reactivation among those who received famciclovir 250 mg three times daily. Four of these patients responded to increased dosages of 500 mg three times daily and did not develop hepatitis. The remaining patient suffered from hepatitis related to hepatitis B virus reactivation. Compared to historical controls, there were fewer cases of hepatitis due to hepatitis B virus reactivation and veno-occlusive disease. The median follow-up was 701.6 days (range: 50-2346 days) with ten deaths (three due to hepatic failure related to HBV reactivation) in those who did not receive famciclovir and one death (due to hepatic failure related to graft-versus-host disease) in those who received famciclovir. Conclusions: Use of famciclovir significantly reduced hepatitis due to hepatitis B virus reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation.
Persistent Identifierhttp://hdl.handle.net/10722/162247
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLau, GKKen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorWu, PCen_US
dc.contributor.authorLee, CKen_US
dc.contributor.authorLim, WLen_US
dc.contributor.authorAu, WYen_US
dc.date.accessioned2012-09-05T05:18:22Z-
dc.date.available2012-09-05T05:18:22Z-
dc.date.issued1998en_US
dc.identifier.citationJournal Of Hepatology, 1998, v. 28 n. 3, p. 359-368en_US
dc.identifier.issn0168-8278en_US
dc.identifier.urihttp://hdl.handle.net/10722/162247-
dc.description.abstractBackground/Aims: Reactivation of chronic hepatitis B viral infection causes significant morbidity and mortality after bone marrow transplantation. Recently, nucleoside analogues, such as famciclovir, were found to have a direct suppressive effect on hepatitis B virus replication in both in vitro and in vivo studies. We have studied the effect of famciclovir on the incidence of hepatitis B virus reactivation and hepatitis after allogeneic bone marrow transplantation. Methods: Eight hepatitis B surface antigen (HBsAg)-positive patients who received allogeneic bone marrow transplantation were given oral famciclovir 250 mg three times daily, starting at least 1 week prior to bone marrow transplantation and continuing for 24 weeks after transplantation. Clinical and serological outcomes in these patients were compared with 24 HBsAg-positive recipients of allogeneic bone marrow transplantation who did not receive famciclovir (historical controls). Results: After bone marrow transplantation, there were five patients with hepatitis B virus reactivation among those who received famciclovir 250 mg three times daily. Four of these patients responded to increased dosages of 500 mg three times daily and did not develop hepatitis. The remaining patient suffered from hepatitis related to hepatitis B virus reactivation. Compared to historical controls, there were fewer cases of hepatitis due to hepatitis B virus reactivation and veno-occlusive disease. The median follow-up was 701.6 days (range: 50-2346 days) with ten deaths (three due to hepatic failure related to HBV reactivation) in those who did not receive famciclovir and one death (due to hepatic failure related to graft-versus-host disease) in those who received famciclovir. Conclusions: Use of famciclovir significantly reduced hepatitis due to hepatitis B virus reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation.en_US
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhepen_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.rightsJournal of Hepatology. Copyright © Elsevier BV.-
dc.subjectAllogeneic Bone Marrow Transplantationen_US
dc.subjectFamcicloviren_US
dc.subjectHepatitis Ben_US
dc.titleUse of famciclovir to prevent HPV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantationen_US
dc.typeArticleen_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0168-8278(98)80307-3en_US
dc.identifier.pmid9551671-
dc.identifier.scopuseid_2-s2.0-0032008570en_US
dc.identifier.hkuros30534-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032008570&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume28en_US
dc.identifier.issue3en_US
dc.identifier.spage359en_US
dc.identifier.epage368en_US
dc.identifier.isiWOS:000072420600001-
dc.publisher.placeNetherlandsen_US
dc.identifier.scopusauthoridLau, GKK=7102301257en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridWu, PC=7403119323en_US
dc.identifier.scopusauthoridLee, CK=36087620900en_US
dc.identifier.scopusauthoridLim, WL=24492170000en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats